CCM
AUPH icon

Chiron Capital Management’s Aurinia Pharmaceuticals AUPH Stock Holding History

Chiron Capital Management’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-10,200
Closed -$233K – 124
2021
Q4 		$233K Sell
10,200
-3,300
-24% -$78.2K 0.17% 97
2021
Q3 		$299K Buy
13,500
+1,700
+14% +$27K 0.22% 79
2021
Q2 		$153K Buy
11,800
+692
+6% +$8.81K 0.13% 76
2021
Q1 		$144K Buy
+11,108
New +$161K 0.12% 70
2020
Q4 		– Sell
-9,700
Closed -$143K – 108
2020
Q3 		$143K Buy
+9,700
New +$141K 0.12% 87

Other funds holding AUPH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $120B AUM 27.84% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Chiron Capital Management's AUPH Position: Q1 2022 in Review

Chiron Capital Management sold out of Aurinia Pharmaceuticals (AUPH) in Q1 2022, closing a stake of 10,200 shares — an estimated $233K sold.

Chiron Capital Management first reported a position in AUPH in Q3 2020 and held it in 5 quarters. The position peaked at $299K in Q3 2021. 184 funds tracked by Wall St. Rank hold AUPH as of Q1 2022.

  • Chiron Capital Management reported no remaining Aurinia Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • Chiron Capital Management sold 10,200 Aurinia Pharmaceuticals shares in Q1 2022, an estimated $233K.
  • Chiron Capital Management first reported a position in Aurinia Pharmaceuticals in Q3 2020 and held it in 5 quarters.
  • Chiron Capital Management's Aurinia Pharmaceuticals position peaked at $299K in Q3 2021.
  • 184 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q1 2022.

Based on Chiron Capital Management's 13F filing for Q1 2022, filed 18 Apr 2022.